MedTrace Logo

[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients

NCT06738862 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2026-03-05

No results posted yet for this study

Summary

The main objective of this study is to establish a standardized method for \[18F\] - FD17 PET imaging in α-synucleinopathy patients, and to analyze its physiological distribution in healthy individuals as well as its pathological distribution in α-synucleinopathy patients, including Parkinson's disease (PD), multiple system atrophy (MSA), and idiopathic rapid-eye-movement sleep behavior disorder (iRBD). Specifically, \[18F\] - FD17 PET imaging focuses on evaluating the deposition of α-synuclein and exploring the diagnostic value of \[18F\] - FD17 PET in PD, MSA, and iRBD patients. In addition, for PD, MSA and RBD patients, dopamine transporter(DAT)-PET imaging was performed to evaluate the distribution and density of DAT in brain. The study aims not only to clarify the specific binding mode of the imaging agent in different α-synucleinopathies, but also to evaluate its efficacy and potential application prospects in early diagnosis , providing new methods for the diagnosis and treatment of neurodegenerative diseases. This study is expected to contribute to early pathological detection and accurate diagnosis in clinical practice.

Conditions

  • α-synucleinopathy
  • Parkinson's Disease (PD)
  • Multiple System Atrophy
  • Rapid Eye Movement Sleep Behavior Disorder
  • PET

Interventions

OTHER

PET

\[18F\] - FD17 PET imaging

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-14
Primary Completion
2025-12-25
Completion
2025-12-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738862 on ClinicalTrials.gov